Skip to main content
. 2022 Mar 10;2022:5687832. doi: 10.1155/2022/5687832

Figure 5.

Figure 5

Lico A overcomes gefitinib resistance in vivo. (a) The tumor volumes of HCC827-GR-derived xenograft tumors with vehicle or Lico A treatment. ∗∗∗p < 0.001. (b) Tumor weight of vehicle- or Lico A-treated xenograft tumors. ∗∗∗p < 0.001. Scale bar, 1 cm. (c) The body weight of tumor-bearing mouse with vehicle or Lico A treatment. (d) Immunohistochemical staining analysis of ki67 and c-Met in vehicle- or Lico A-treated xenograft tumors. (e) Qualification analysis of ki67 and c-Met staining from (d). ∗∗∗p < 0.001. Scale bar, 25 μM. (f) A schematic illustration representing Licochalcone A inhibits c-Met signaling by promoting c-Cbl-mediated c-Met ubiquitination.